Clinical Trial Update: Thalidomide Anti-Angiogenesis Therapy of Relapsed or Refractory Leukemia [Phase 2]

View source ↗

Summary

This update covers a Phase 2 clinical trial evaluating thalidomide as anti-angiogenesis therapy for relapsed or refractory leukemia. The study status is complet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia

Drugs mentioned

• Thalidomide (thalidomide)

Snippet

Sponsor: University of Arkansas | Conditions: Leukemia | Phase 2 | Status: COMPLETED